Lilly to Separate Elanco Animal Health with IPO

Eli Lilly and Company宣布它已完成对Elanco Animal Health的战略审查，并将在未来几周内提出注册声明，并为美国证券交易委员会（SEC）为少数群体所有权股权的潜在首次公开发行（IPO）在Elanco作为一个单独的公司。

The offering is expected to represent an ownership stake of less than 20%. The number of shares to be offered and the price range for the offering have not yet been determined. The company expects to complete the IPO process during the second half of 2018.

对于Lilly的财务报告，Lilly将继续在其财务业绩中巩固Elanco。莉莉计划通过税收交易剥夺其其余所有权。执行IPO取决于 - 并受到许多因素和不确定性，包括商业和市场条件。

“Based on our strategic review, we concluded that after-tax value for Lilly shareholders would be maximized by pursuing an initial public offering of Elanco,” says David A. Ricks, Lilly’s chairman and CEO. “We believe this will allow Elanco to efficiently deploy its resources to those growth opportunities that best serve its customers. In addition, this will provide Lilly even greater focus on the human pharmaceutical business to pursue our purpose of creating life-changing medicines for patients.”

With more than six decades of expertise in animal health, Elanco Animal Health is prepared to take this step to become an independent company, says Jeffrey Simmons, president.

“With a sole focus on animal health, we will help our customers address the greatest challenges of keeping animals healthy, and together advance a vision of food and companionship enriching life," he adds.